Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02250651 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 528
- Enrollment target
NCT02250651 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 528 participants.
The verdict
NCT02250651, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 528 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
Interventions
- DRUG Bimatoprost SR
- DRUG Active Comparator: Timolol 0.5%
- OTHER Sham: Applicator Without Needle
- DRUG Timolol Vehicle (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 528 participants |
| Start Date | 2014-12-15 |
| Est. Completion | 2020-07-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02250651
The ClinicalTrials.gov registry entry for NCT02250651 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 528 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bimatoprost SR is the first listed.
NCT02250651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02250651 about?
NCT02250651 is a clinical study titled "Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension". This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
What is the current status of trial NCT02250651?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 528 participants. The study started on 2014-12-15. Estimated completion is 2020-07-22.
What interventions are being tested in trial NCT02250651?
The interventions under investigation include: Bimatoprost SR (DRUG), Active Comparator: Timolol 0.5% (DRUG), Sham: Applicator Without Needle (OTHER), Timolol Vehicle (placebo) (DRUG).
Who is sponsoring clinical trial NCT02250651?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.